Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease

Abstract

Traditionally regarded as a metabolic waste product, lactic acid is now recognized as a crucial molecule in energy metabolism and signal transduction. It regulates various biological processes, including intracellular inflammation and immune responses. Notably, a novel epigenetic modification, lactylation, which is directly linked to lactic acid, was first identified by Professor Zhao Yingming's team in 2019. Lactylation influences gene expression and is associated with inflammation, cancer, and ischemic disease. Despite its potential significance, the precise mechanisms by which lactylation regulates gene expression remain unclear, and its implications in cardiovascular diseases are not yet fully understood. This review elucidates the relationship between lactic acid metabolism and cellular functions, highlighting its significant biological roles. This review provides a comprehensive analysis of the mechanistic role of lactylation in disease progression. It synthesizes research findings and emerging trends concerning lactic acid production and lactylation in the context of cardiovascular diseases. We explored potential therapeutic agents targeting lactylation and identified prospective treatment targets, offering novel insights into and directions for intervention strategies related to lactic acid production and lactylation. Ultimately, this review aims to pave the way for new therapeutic and research avenues in cardiovascular diseases.

Keywords

cardiovascular disease / cellular metabolism / immunotherapy / lactylation / lactic acid

References

[1] C. W. Tsao, A. W. Aday, Z. I. Almarzooq, et al., “Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association,” Circulation 147, no. 8 (2023): E93-E621.

[2] G. Mensah, V. Fuster, and G. Roth, “A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action,” Journal of the American College of Cardiology 82, no. 25 (2023): 2343-2349.

[3] G. D. Lopaschuk, Q. G. Karwi, R. Tian, A. R. Wende, and E. D. Abel, “Cardiac Energy Metabolism in Heart Failure,” Circulation Research 128, no. 10 (2021): 1487-1513.

[4] T. Rubio-Tomás, C. Soler-Botija, O. Martínez-Estrada, and J. A. Villena, “Transcriptional Control of Cardiac Energy Metabolism in Health and Disease: Lessons From Animal Models,” Biochemical Pharmacology 224 (2024): 116185.

[5] A. M. de Waard, M. Hollander, J. C. Korevaar, et al., “Selective Prevention of Cardiometabolic Diseases: Activities and Attitudes of General Practitioners Across Europe,” European Journal of Public Health 29, no. 1 (2019): 88-93.

[6] H. Tian, X. Zhao, Y. Zhang, and Z. Xia, “Abnormalities of Glucose and Lipid Metabolism in Myocardial Ischemia-Reperfusion Injury,” Biomedicine & Pharmacotherapy 163 (2023): 114827.

[7] T. T. Nguyen, S. Wei, T. H. Nguyen, et al., “Mitochondria-Associated Programmed Cell Death as a Therapeutic Target for Age-Related Disease,” Experimental and Molecular Medicine 55, no. 8 (2023): 1595-1619.

[8] Z. Ling, Y. Jiang, J. Ru, J. Lu, B. Ding, and J. Wu, “Amino Acid Metabolism in Health and Disease,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 345.

[9] S. R. Yurista, C. Chong, J. J. Badimon, D. P. Kelly, R. A. de Boer, and B. D. Westenbrink, “Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease JACC State-of-the-Art Review,” Journal of the American College of Cardiology 77, no. 13 (2021): 1660-1669.

[10] G. G. Schiattarella, Y. Wang, R. Tian, and J. A. Hill, “Metabolism and Inflammation in Cardiovascular Health and Diseases: Mechanisms to Therapies,” Journal of Molecular and Cellular Cardiology 157 (2021): 113-114.

[11] M. Zhang, Q. Deng, L. Wang, et al., “Prevalence of Dyslipidemia and Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Adults: A Nationally Representative Survey of 163,641 Adults,” International Journal of Cardiology 260 (2018): 196-203.

[12] D. Wishart, “Metabolomics for Investigating Physiological and Pathophysiological Processes,” Physiological Reviews 99, no. 4 (2019): 1819-1875.

[13] J. R. Ussher, S. Elmariah, R. E. Gerszten, and J. R. Dyck, “The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease,” Journal of the American College of Cardiology 68, no. 25 (2016): 2850-2870.

[14] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575-580.

[15] F. Merkuri, M. Rothstein, and M. Simoes-Costa, “Histone Lactylation Couples Cellular Metabolism With Developmental Gene Regulatory Networks,” Nature Communications 15, no. 1 (2024): 90.

[16] X. Dai, X. Lv, E. W. Thompson, and K. Ostrikov, “Histone Lactylation: Epigenetic Mark of Glycolytic Switch,” Trends in Genetics 38, no. 2 (2022): 124-127.

[17] Z. Liao, B. Chen, T. Yang, W. Zhang, and Z. Mei, “Lactylation Modification in Cardio-Cerebral Diseases: A State-of-the-Art Review,” Ageing Research Reviews 104 (2025): 102631.

[18] M. L. Taddei, L. Pietrovito, A. Leo, and P. Chiarugi, “Lactate in Sarcoma Microenvironment: Much More Than just a Waste Product,” Cells 9, no. 2 (2020): 510.

[19] R. McNeillis, A. Greystoke, J. Walton, et al., “A Case of Malignant Hyperlactaemic Acidosis Appearing Upon Treatment With the Mono-Carboxylase Transporter 1 Inhibitor AZD3965,” British Journal of Cancer 122, no. 8 (2020): 1141-1145.

[20] A. J. Lasprilla, G. A. Martinez, B. H. Lunelli, A. L. Jardini, and R. M. Filho, “Poly-Lactic Acid Synthesis for Application in Biomedical Devices—A Review,” Biotechnology Advances 30, no. 1 (2012): 321-328.

[21] D. Schuetterle R. Hegnera, M. Temovskaa, A. E. Ortiz-Ardilaa, and L. T. Angenent, “Exclusive D-Lactate-Isomer Production During a Reactor-Microbiome Conversion of Lactose-Rich Waste by Controlling pH and Temperature,” Water Research 250 (2024).

[22] X. Li, Y. Yang, B. Zhang, et al., “Lactate Metabolism in Human Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 305.

[23] P. Apostolova and E. Pearce, “Lactic Acid and Lactate: Revisiting the Physiological Roles in the Tumor Microenvironment,” Trends in Immunology 43, no. 12 (2022): 969-977.

[24] L. Chen, L. Huang, Y. Gu, W. Cang, P. Sun, Y. Xiang, “Lactate-Lactylation Hands Between Metabolic Reprogramming and Immunosuppression,” International Journal of Molecular Sciences 23, no. 19 (2022): 11943.

[25] P. Vaupel and G. Multhoff, “Revisiting the Warburg Effect: Historical Dogma Versus< Current Understanding,” Journal of Physiology-London 599, no. 6 (2021): 1745-1757.

[26] J. Rabinowitz and S. Enerbäck, “Lactate: The Ugly Duckling of Energy Metabolism,” Nature Metabolism 2, no. 7 (2020): 566-571.

[27] O. Warburg, F. Wind, and E. Negelein, “The Metabolism of Tumors in the Body,” Journal of General Physiology 8, no. 6 (1927): 519-530.

[28] P. Vaupel and G. Multhoff, “Revisiting the Warburg Effect: Historical Dogma Versus Current Understanding,” The Journal of Physiology 599, no. 6 (2021): 1745-1757.

[29] A. M. Abdel-Haleem, N. E. Lewis, N. Jamshidi, K. Mineta, X. Gao, and T. Gojobori, “The Emerging Facets of Non-Cancerous Warburg Effect,” Frontiers in Endocrinology (Lausanne) 8 (2017): 279.

[30] P. Wu, T. Zhu, Y. Huang, Z. Fang, and F. Luo, “Current Understanding of the Contribution of Lactate to the Cardiovascular System and its Therapeutic Relevance,” Frontiers in Endocrinology (Lausanne) 14 (2023): 1205442.

[31] M. Ajam-Hosseini, R. Heydari, M. Rasouli, et al., “Lactic Acid in Macrophage Polarization: A Factor in Carcinogenesis and a Promising Target for Cancer Therapy,” Biochemical Pharmacology 222 (2024): 116098.

[32] M. A. Felmlee, R. S. Jones, V. Rodriguez-Cruz, K. E. Follman, and M. E. Morris, “Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease,” Pharmacological Reviews 72, no. 2 (2020): 466-485.

[33] L. Ippolito, A. Morandi, E. Giannoni, and P. Chiarugi, “Lactate: A Metabolic Driver in the Tumour Landscape,” Trends in Biochemical Sciences 44, no. 2 (2019): 153-166.

[34] B. S. Ferguson, M. J. Rogatzki, M. L. Goodwin, D. A. Kane, Z. Rightmire, and L. B. Gladden, “Lactate Metabolism: Historical Context, Prior Misinterpretations, and Current Understanding,” European Journal of Applied Physiology 118, no. 4 (2018): 691-728.

[35] S. Hui, J. M. Ghergurovich, R. J. Morscher, et al., “Glucose Feeds the TCA Cycle Via Circulating Lactate,” Nature 551, no. 7678 (2017): 115-+.

[36] X. Cai, C. P. Ng, O. Jones, et al., “Lactate Activates the Mitochondrial Electron Transport Chain Independently of its Metabolism,” Molecular Cell 83, no. 21 (2023): 3904-3920.e7.

[37] B. S. Ferguson, M. J. Rogatzki, M. L. Goodwin, D. A. Kane, Z. Rightmire, and L. B. Gladden, “Lactate Metabolism: Historical Context, Prior Misinterpretations, and Current Understanding,” European Journal of Applied Physiology 118, no. 4 (2018): 691-728.

[38] W. Liu, Y. Wang, L. H. M. Bozi, et al., “Lactate Regulates Cell Cycle by Remodelling the Anaphase Promoting Complex,” Nature 616, no. 7958 (2023): 790-797.

[39] D. Lee, H. Sohn, Z. Park, et al., “A Lactate-Induced Response to Hypoxia,” Cell 161, no. 3 (2015): 595-609.

[40] T. K. Hunt, R. S. Aslam, S. Beckert, et al., “Aerobically Derived Lactate Stimulates Revascularization and Tissue Repair Via Redox Mechanisms,” Antioxidants & Redox Signaling 9, no. 8 (2007): 1115-1124.

[41] S. Beckert, F. Farrahi, R. S. Aslam, et al., “Lactate Stimulates Endothelial Cell Migration,” Wound Repair and Regeneration 14, no. 3 (2006): 321-324.

[42] T. Brown and V. Ganapathy, “Lactate/GPR81 Signaling and Proton Motive Force in Cancer: Role in Angiogenesis, Immune Escape, Nutrition, and Warburg Phenomenon,” Pharmacology & Therapeutics 206 (2020): 107451.

[43] F. Végran, R. Boidot, C. Michiels, P. Sonveaux, and O. Feron, “Lactate Influx Through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF-κB/IL-8 Pathway that Drives Tumor Angiogenesis,” Cancer Research 71, no. 7 (2011): 2550-2560.

[44] H. Shime, M. Yabu, T. Akazawa, et al., “Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway,” Journal of Immunology 180, no. 11 (2008): 7175-7183.

[45] J. Yang, G. R. Gourley, A. Gilbertsen, et al., “High Glucose Levels Promote Switch to Synthetic Vascular Smooth Muscle Cells via Lactate/GPR81,” Cells 13, no. 3 (2024): 236.

[46] K. Ahmed, S. Tunaru, C. Tang, et al., “An Autocrine Lactate Loop Mediates Insulin-Dependent Inhibition of Lipolysis Through GPR81,” Cell Metabolism 11, no. 4 (2010): 311-319.

[47] V. Bianchi, “Impact of Nutrition on Cardiovascular Function,” Current Problems in Cardiology 45, no. 1 (2020): 100391.

[48] G. Rosano and C. Vitale, “Metabolic Modulation of Cardiac Metabolism in Heart Failure,” Cardiac Failure Review 4, no. 2 (2018): 99-103.

[49] H. Li, Z. Ma, Y. Zhai, et al., “Trimetazidine Ameliorates Myocardial Metabolic Remodeling in Isoproterenol-Induced Rats Through Regulating Ketone Body Metabolism via Activating AMPK and PPAR α,” Frontiers in Pharmacology 11 (2020): 1255.

[50] K. Wallenius, P. Thalén, J. Björkman, et al., “Involvement of the Metabolic Sensor GPR81 in Cardiovascular Control,” JCI Insight 2, no. 19 (2017): e92564.

[51] P. Ranganathan, A. Shanmugam, D. Swafford, et al., “GPR81, a Cell-Surface Receptor for Lactate, Regulates Intestinal Homeostasis and Protects Mice From Experimental Colitis,” Journal of Immunology 200, no. 5 (2018): 1781-1789.

[52] X. Cheng, K. Wang, Y. Zhao, and K. Wang, “Research Progress on Post-Translational Modification of Proteins and Cardiovascular Diseases,” Cell Death Discovery 9, no. 1 (2023): 275.

[53] S. Costantino, P. Libby, R. Kishore, J. Tardif, A. El-Osta, and F. Paneni, “Epigenetics and Precision Medicine in Cardiovascular Patients: From Basic Concepts to the Clinical Arena,” European Heart Journal 39, no. 47 (2018): 4150-4158.

[54] L. Izzo and K. Wellen, “Histone Lactylation Links Metabolism and Gene Regulation,” Nature 574, no. 7779 (2019): 492-493.

[55] K. Xu, K. Zhang, Y. Wang, and Y. Gu, “Comprehensive Review of Histone Lactylation: Structure, Function, and Therapeutic Targets,” Biochemical Pharmacology 225 (2024): 116331.

[56] N. Wan, N. Wang, S. Yu, et al., “Cyclic Immonium Ion of Lactyllysine Reveals Widespread Lactylation in the Human Proteome,” Nature Methods 19, no. 7 (2022): 854-+.

[57] J. Wang, Z. Wang, Q. Wang, X. Li, and Y. Guo, “Ubiquitous Protein Lactylation in Health and Diseases,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 23.

[58] D. O. Gaffney, E. Q. Jennings, C. C. Anderson, et al., “Non-Enzymatic Lysine Lactoylation of Glycolytic Enzymes,” Cell Chemical Biology 27, no. 2 (2020): 206-213.e6.

[59] H. Gong, H. Zhong, L. Cheng, L. Li, and D. Zhang, “Post-Translational Protein Lactylation Modification in Health And Diseases: A Double-Edged Sword,” Journal of Translational Medicine 22, no. 1 (2024): 41.

[60] N. Zhang, Y. Zhang, J. Xu, et al., “α-Myosin Heavy Chain Lactylation Maintains Sarcomeric Structure and Function and Alleviates the Development of Heart Failure,” Cell Research 33, no. 9 (2023): 679-698.

[61] K. Yang, M. Fan, X. Wang, et al., “Lactate Promotes Macrophage HMGB1 Lactylation, Acetylation, and Exosomal Release in Polymicrobial Sepsis,” Cell Death and Differentiation 29, no. 1 (2022): 133-146.

[62] H. Dong, J. Zhang, H. Zhang, et al., “YiaC and CobB Regulate Lysine Lactylation in Escherichia coli,” Nature Communications 13, no. 1 (2022): 6628.

[63] Z. Niu, C. Chen, S. Wang, et al., “HBO1 Catalyzes Lysine Lactylation and Mediates Histone H3K9la to Regulate Gene Transcription,” Nature Communications 15, no. 1 (2024): 3561.

[64] C. Moreno-Yruela, D. Zhang, W. Wei, et al., “Class I Histone Deacetylases (HDAC1-3) are Histone Lysine Delactylases,” Science Advances 8, no. 3 (2022): eabi6696.

[65] H. Zu, C. Li, C. Dai, et al., “SIRT2 Functions as a Histone Delactylase and Inhibits the Proliferation and Migration of Neuroblastoma Cells,” Cell Discovery 8, no. 1 (2022): 54.

[66] G. Figlia, P. Willnow, and A. Teleman, “Metabolites Regulate Cell Signaling and Growth via Covalent Modification of Proteins,” Developmental Cell 54, no. 2 (2020): 156-170.

[67] R. P. Vermeulen, M. Hoekstra, M. W. Nijsten, et al., “Clinical Correlates of Arterial Lactate Levels in Patients With ST-Segment Elevation Myocardial Infarction at Admission: A Descriptive Study,” Critical Care (London, England) 14, no. 5 (2010): R164.

[68] P. M. Davierwala, S. Leontyev, A. Verevkin, et al., “Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for Cardiogenic Shock Complicating Acute Myocardial Infarction,” Circulation 134, no. 17 (2016): 1224-1237.

[69] R. Zymliński, J. Biegus, M. Sokolski, et al., “Increased Blood Lactate is Prevalent and Identifies Poor Prognosis in Patients With Acute Heart Failure Without Overt Peripheral Hypoperfusion,” European Journal of Heart Failure 20, no. 6 (2018): 1011-1018.

[70] U. Ceglarek, P. Schellong, M. Rosolowski, et al., “The Novel Cystatin C, Lactate, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide (CLIP)-Based Mortality Risk Score in Cardiogenic Shock After Acute Myocardial Infarction,” European Heart Journal 42, no. 24 (2021): 2344-2352.

[71] N. Stevic, L. Argaud, J. Loufouat, et al., “Molar Sodium Lactate Attenuates the Severity of Postcardiac Arrest Syndrome: A Preclinical Study,” Critical Care Medicine 50, no. 1 (2022): e71-e79.

[72] X. Chang, W. Zheng, Y. Zhao, et al., “Association of Lactate With Risk of Cardiovascular Diseases: A Two-Sample Mendelian Randomization Study,” Vascular Health and Risk Management 20 (2024): 541-551.

[73] M. Terlecki, M. Kocowska-Trytko, K. Plens, et al., “Prognostic Value of Acid‑Base Balance Parameters Assessed on Admission in Peripheral Venous Blood of Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention,” Polish Archives of Internal Medicine 132, no. 6 (2022): 16229.

[74] J. Pöss, J. Köster, G. Fuernau, et al., “Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction,” Journal of the American College of Cardiology 69, no. 15 (2017): 1913-1920.

[75] H. Li, J. Chen, X. Xing, and D. Lou, “Association of Lactate Detection With in-Hospital Mortality in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study,” BMJ Open 13, no. 4 (2023): e069129.

[76] D. Liang, X. Zhou, X. Hong, et al., “Association Between Admission Lactate Levels and Mortality in Patients With Acute Coronary Syndrome: A Retrospective Cohort Study,” Coronary Artery Disease 30, no. 1 (2019): 26-32.

[77] G. P. S. Shantha, B. Wasserman, B. C. Astor, et al., “Association of Blood Lactate With Carotid Atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study,” Atherosclerosis 228, no. 1 (2013): 249-255.

[78] Z. Sun, Y. Han, S. Song, T. Chen, Y. Han, and Y. Liu, “Activation of GPR81 by Lactate Inhibits Oscillatory Shear Stress-Induced Endothelial Inflammation by Activating the Expression of KLF2,” Iubmb Life 71, no. 12 (2019): 2010-2019.

[79] L. Yang, L. Gao, T. Nickel, et al., “Lactate Promotes Synthetic Phenotype in Vascular Smooth Muscle Cells,” Circulation Research 121, no. 11 (2017): 1251-1262.

[80] A. Gizak, J. McCubrey, and D. Rakus, “Cell-to-Cell Lactate Shuttle Operates in Heart and is Important in Age-Related Heart Failure,” Aging (Albany NY) 12, no. 4 (2020): 3388-3406.

[81] C. Bastian, J. Quinn, C. Doherty, et al., “Role of Brain Glycogen During Ischemia, Aging and Cell-to-Cell Interactions,” Advanced Neurobiology 23 (2019): 347-361.

[82] S. J. Geiseler, A. Hadzic, M. Lambertus, et al., “L-Lactate Treatment at 24 h and 48 h After Acute Experimental Stroke Is Neuroprotective via Activation of the L-Lactate Receptor HCA(1),” International Journal of Molecular Sciences 25, no. 2 (2024): 1232.

[83] Z. Shen, L. Jiang, Y. Yuan, et al., “Inhibition of G Protein-Coupled Receptor 81 (GPR81) Protects Against Ischemic Brain Injury,” CNS Neuroscience & Therapeutics 21, no. 3 (2015): 271-279.

[84] D. Sappey-Marinier, L. Chileuitt, P. R. Weinstein, M. W. Weiner, and A. I. Faden, “Hypoglycemia Prevents Increase in Lactic Acidosis During Reperfusion After Temporary Cerebral Ischemia in Rats,” Nmr in Biomedicine 8, no. 4 (1995): 171-178.

[85] S. Wohnsland, H. F. Bürgers, W. Kuschinsky, and M. H. Maurer, “Neurons and Neuronal Stem Cells Survive In Glucose-Free Lactate and in High Glucose Cell Culture Medium During Normoxia and Anoxia,” Neurochemical Research 35, no. 10 (2010): 1635-1642.

[86] Y. Zheng and X. Wang, “Expression Changes in Lactate and Glucose Metabolism and Associated Transporters in Basal Ganglia following Hypoxic-Ischemic Reperfusion Injury in Piglets,” Ajnr American Journal of Neuroradiology 39, no. 3 (2018): 569-576.

[87] S. Ghatak, A. Banerjee, and S. Sikdar, “Ischaemic Concentrations of Lactate Increase TREK1 Channel Activity by Interacting With a Single Histidine Residue in the Carboxy Terminal Domain,” The Journal of Physiology 594, no. 1 (2016): 59-81.

[88] E. Haege, H. Huang, and C. Huang, “Identification of Lactate as a Cardiac Protectant by Inhibiting Inflammation and Cardiac Hypertrophy Using a Zebrafish Acute Heart Failure Model,” Pharmaceuticals (Basel) 14, no. 3 (2021): 261.

[89] M. Nalos, X. M. Leverve, S. J. Huang, et al., “Half-Molar Sodium Lactate Infusion Improves Cardiac Performance in Acute Heart Failure: A Pilot Randomised Controlled Clinical Trial,” Critical Care (London, England) 18, no. 2 (2014): R48.

[90] J. Biegus, R. Zymliński, M. Sokolski, P. Gajewski, W. Banasiak, and P. Ponikowski, “Clinical, Respiratory, Haemodynamic, and Metabolic Determinants of Lactate in Heart Failure,” Kardiologia Polska 77, no. 1 (2019): 47-52.

[91] C. Dai, Q. Li, H. I. May, et al., “Lactate Dehydrogenase A Governs Cardiac Hypertrophic Growth in Response to Hemodynamic Stress,” Cell Reports 32, no. 9 (2020): 108087.

[92] A. A. Cluntun, R. Badolia, S. Lettlova, et al., “The Pyruvate-Lactate Axis Modulates Cardiac Hypertrophy and Heart Failure,” Cell Metabolism 33, no. 3 (2021): 629-648.e10.

[93] C. Chen, F. Luo, P. Wu, et al., “Metabolomics Reveals Metabolite Changes of Patients With Pulmonary Arterial Hypertension in China,” Journal of Cellular and Molecular Medicine 24, no. 4 (2020): 2484-2496.

[94] X. Deng, N. Jiang, C. Huang, et al., “Mortality and Prognostic Factors in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Patients Complicated With Right Heart Failure,” International Journal of Rheumatic Diseases 26, no. 5 (2023): 862-869.

[95] R. Tuder, “Pathology of Pulmonary Arterial Hypertension,” Seminars in Respiratory and Critical Care Medicine 30, no. 4 (2009): 376-385.

[96] M. Rabinovitch, “Molecular Pathogenesis of Pulmonary Arterial Hypertension,” Journal of Clinical Investigation 118, no. 7 (2008): 2372-2379.

[97] D. Wu, S. Wang, F. Wang, Q. Zhang, Z. Zhang, and X. Li, “Lactate Dehydrogenase A (LDHA)-Mediated Lactate Generation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension,” Journal of Translational Medicine 22, no. 1 (2024): 738.

[98] L. Kovacs, Y. Cao, W. Han, et al., “PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension,” American Journal of Respiratory and Critical Care Medicine 200, no. 5 (2019): 617-627.

[99] K. Moore, F. Sheedy, and E. Fisher, “Macrophages in Atherosclerosis: A Dynamic Balance,” Nature Reviews Immunology 13, no. 10 (2013): 709-721.

[100] A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes,” Trends in Immunology 23, no. 11 (2002): 549-555.

[101] T. Barrett, “Macrophages in Atherosclerosis Regression,” Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 1 (2020): 20-33.

[102] K. Rahman, Y. Vengrenyuk, S. A. Ramsey, et al., “Inflammatory Ly6Chi Monocytes and Their Conversion to M2 Macrophages Drive Atherosclerosis Regression,” Journal of Clinical Investigation 127, no. 8 (2017): 2904-2915.

[103] Y. Liu, R. Xu, H. Gu, et al., “Metabolic Reprogramming in Macrophage Responses,” Biomarker Research 9, no. 1 (2021): 1.

[104] M. Locati, G. Curtale, and A. Mantovani, “Diversity, Mechanisms, and Significance of Macrophage Plasticity,” Annual Review of Pathology 15 (2020): 123-147.

[105] M. Shu, D. Lu, Z. Zhu, F. Yang, and Z. Ma, “Insight Into the Roles of Lactylation in Macrophages: Functions and Clinical Implications,” Clinical Science (London, England: 1979) 139, no. 2 (2025): CS20242737.

[106] X. Xu, D. Zhang, P. Kong, et al., “Sox10 Escalates Vascular Inflammation by Mediating Vascular Smooth Muscle Cell Transdifferentiation and Pyroptosis in Neointimal Hyperplasia,” Cell Reports 42, no. 8 (2023).

[107] Y. Zhang, H. Jiang, M. Dong, et al., “Macrophage MCT4 Inhibition Activates Reparative Genes and Protects From Atherosclerosis by Histone H3 Lysine 18 Lactylation,” Cell Reports 43, no. 5 (2024): 114180.

[108] Y. Wang, L. Chen, M. Zhang, et al., “Exercise-Induced Endothelial Mecp2 Lactylation Suppresses Atherosclerosis Via the Ereg/MAPK Signalling Pathway,” Atherosclerosis 375 (2023): 45-58.

[109] M. Fan, K. Yang, X. Wang, et al., “Lactate Promotes Endothelial-to-Mesenchymal Transition Via Snail1 Lactylation After Myocardial Infarction,” Science Advances 9, no. 5 (2023): eadc9465.

[110] Z. Hou, W. Yan, T. Li, et al., “Lactic Acid-Mediated Endothelial to Mesenchymal Transition Through TGF-β1 Contributes to in-stent Stenosis in poly-L-Lactic Acid Stent,” International Journal of Biological Macromolecules 155 (2020): 1589-1598.

[111] N. Wang, W. Wang, X. Wang, et al., “Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction,” Circulation Research 131, no. 11 (2022): 893-908.

[112] G. Xu, P. Yu, Y. Hu, et al., “Exercise Training Decreases Lactylation and Prevents Myocardial Ischemia-Reperfusion Injury by Inhibiting YTHDF2,” Basic Research in Cardiology 119, no. 4 (2024): 651-671.

[113] W. Yu, Q. Kong, S. Jiang, et al., “HSPA12A Maintains Aerobic Glycolytic Homeostasis and Histone3 Lactylation in Cardiomyocytes to Attenuate Myocardial Ischemia/Reperfusion Injury,” JCI Insight 9, no. 7 (2024): e169125.

[114] L. Wang, D. Li, F. Yao, et al., “Serpina3k Lactylation Protects From Cardiac Ischemia Reperfusion Injury,” Nature Communications 16, no. 1 (2025): 1012.

[115] X. Yao and C. Li, “Lactate Dehydrogenase A Mediated Histone Lactylation Induced the Pyroptosis Through Targeting HMGB1,” Metabolic Brain Disease 38, no. 5 (2023): 1543-1553.

[116] W. Zhang, L. Xu, Z. Yu, M. Zhang, J. Liu, and J. Zhou, “Inhibition of the Glycolysis Prevents the Cerebral Infarction Progression Through Decreasing the Lactylation Levels of LCP1,” Molecular Biotechnology 65, no. 8 (2023): 1336-1345.

[117] Y. Yao, R. Bade, G. Li, et al., “Global-Scale Profiling of Differential Expressed Lysine-Lactylated Proteins in the Cerebral Endothelium of Cerebral Ischemia-Reperfusion Injury Rats,” Cellular and Molecular Neurobiology 43, no. 5 (2023): 1989-2004.

[118] X. Wang, W. Fan, N. Li, et al., “YY1 Lactylation in Microglia Promotes Angiogenesis Through Transcription Activation-Mediated Upregulation of FGF2,” Genome Biology 24, no. 1 (2023): 87.

[119] X. Chen, Y. Wang, J. Wang, et al., “Lactylation-Driven FTO Targets CDK2 to Aggravate Microvascular Anomalies in Diabetic Retinopathy,” EMBO Molecular Medicine 16, no. 2 (2024): 294-318.

[120] W. Yang, Z. Li, R. Qin, et al., “YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA,” Frontiers in Oncology 9 (2019): 1187.

[121] Y. Shi, J. Lee, and K. Galvin, “Everything you have ever Wanted to Know About Yin Yang 1,” Biochimica Et Biophysica Acta 1332, no. 2 (1997): F49-66.

[122] M. Thomas and E. Seto, “Unlocking the Mechanisms of Transcription Factor YY1: Are Chromatin Modifying Enzymes the key?,” Gene 236, no. 2 (1999): 197-208.

[123] X. Lin, Y. Lei, M. Pan, et al., “Augmentation of Scleral Glycolysis Promotes Myopia Through Histone Lactylation,” Cell Metabolism 36, no. 3 (2024): 511-525.e7.

[124] Y. Wang, H. Li, S. Jiang, et al., “The Glycolytic Enzyme PFKFB3 Drives Kidney Fibrosis Through Promoting Histone Lactylation-Mediated NF-κB Family Activation,” Kidney International 106, no. 2 (2024): 226-240.

[125] L. Peterson and R. Gropler, “Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy,” Circulation Research 126, no. 11 (2020): 1628-1645.

[126] X. M. Ma, K. Geng, P. Wang, Z. Jiang, B. Y. Law, and Y. Xu, “MCT4-Dependent Lactate Transport: A Novel Mechanism for Cardiac Energy Metabolism Injury and Inflammation in Type 2 Diabetes Mellitus,” Cardiovascular Diabetology 23, no. 1 (2024): 96.

[127] J. Chen, M. Zhang, Y. Liu, et al., “Histone lactylation Driven by mROS-Mediated Glycolytic Shift Promotes Hypoxic Pulmonary Hypertension,” Journal of Molecular Cell Biology 14, no. 12 (2023): mjac073.

[128] L. M. Moncla, M. Briend, Y. Bossé, and P. Mathieu, “Calcific Aortic Valve Disease: Mechanisms, Prevention and Treatment,” Nature Reviews Cardiology 20, no. 8 (2023): 546-559.

[129] C. Wang, S. Wang, Z. Wang, et al., “Andrographolide Regulates H3 Histone Lactylation by Interfering With p300 to Alleviate Aortic Valve Calcification,” British Journal of Pharmacology 181, no. 12 (2024): 1843-1856.

[130] Y. Huang, C. Wang, T. Zhou, et al., “Lumican Promotes Calcific Aortic Valve Disease Through H3 Histone Lactylation,” European Heart Journal 45, no. 37 (2024): 3871-3885.

[131] Y. Lai, W. W. Kao, Y. Yeh, W. Chen, and P. Chu, “Lumican Deficiency Promotes Pulmonary Arterial Remodeling,” Translational Research 237 (2021): 63-81.

[132] F. Baltazar, J. Afonso, M. Costa, and S. Granja, “Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy,” Frontiers in Oncology 10 (2020): 231.

[133] Y. Gao, H. Zhou, G. Liu, J. Wu, Y. Yuan, and A. Shang, “Tumor Microenvironment: Lactic Acid Promotes Tumor Development,” Journal of Immunology Research 2022 (2022): 3119375.

[134] Z. Pennington, M. L. Goodwin, E. M. Westbroek, E. Cottrill, A. K. Ahmed, and D. M. Sciubba, “Lactate and Cancer: Spinal Metastases and Potential Therapeutic Targets (Part 2),” Annals of Translational Medicine 7, no. 10 (2019): 221.

[135] L. Ippolito, A. Morandi, E. Giannoni, and P. Chiarugi, “Lactate: A Metabolic Driver in the Tumour Landscape,” Trends in Biochemical Sciences 44, no. 2 (2019): 153-166.

[136] X. Pan, Y. Zhang, Y. Gan, et al., “Electroacupuncture Pretreatment Reduces Ischemic Brain Injury by Inhibiting the Lactate Production and Its Derived Protein Lactylation Formation,” CNS Neuroscience & Therapeutics 31, no. 1 (2025): e70231.

[137] X. Xiong, X. Pan, X. Luo, et al., “Astrocyte-Derived Lactate Aggravates Brain Injury of Ischemic Stroke in Mice by Promoting the Formation of Protein Lactylation,” Theranostics 14, no. 11 (2024): 4297-4317.

[138] E. M. Bowers, G. Yan, C. Mukherjee, et al., “Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a selective Small Molecule Inhibitor,” Chemistry & Biology 17, no. 5 (2010): 471-482.

[139] X. Yang, Q. Wu, L. Zhang, and L. Feng, “Inhibition of Histone Deacetylase 3 (HDAC3) Mediates Ischemic Preconditioning and Protects Cortical Neurons Against Ischemia in Rats,” Frontiers in Molecular Neuroscience 9 (2016): 131.

[140] Y. Liao, J. Cheng, X. Kong, et al., “HDAC3 Inhibition Ameliorates Ischemia/Reperfusion-Induced Brain Injury by Regulating the Microglial cGAS-STING Pathway,” Theranostics 10, no. 21 (2020): 9644-9662.

[141] A. Murphy and M. Febbraio, “Immune-Based Therapies in Cardiovascular and Metabolic Diseases: Past, Present and Future,” Nature Reviews Immunology 21, no. 10 (2021): 669-679.

[142] A. Lopez Krol, H. P. Nehring, F. F. Krause, et al., “Lactate Induces Metabolic and Epigenetic Reprogramming of Pro-Inflammatory Th17 cells,” Embo Reports 23, no. 12 (2022): e54685.

[143] M. Certo, C. Tsai, V. Pucino, P. Ho, and C. Mauro, “Lactate Modulation of Immune Responses in Inflammatory Versus Tumour Microenvironments,” Nature Reviews Immunology 21, no. 3 (2021): 151-161.

[144] A. Brand, K. Singer, G. Koehl, et al., “LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells,” Cell Metabolism 24, no. 5 (2016): 657-671.

[145] A. Kumar, K. Pyaram, E. L. Yarosz, et al., “Enhanced Oxidative Phosphorylation in NKT Cells is Essential for Their Survival And Function,” PNAS 116, no. 15 (2019): 7439-7448.

[146] Z. Liu, Z. Zhang, Y. Zhang, et al., “Spatial Transcriptomics Reveals that Metabolic Characteristics Define the Tumor Immunosuppression Microenvironment Via iCAF Transformation in Oral Squamous Cell Carcinoma,” Int J Oral Sci 16, no. 1 (2024): 9.

[147] J. Gu, J. Zhou, and Q. Chen, “Tumor Metabolite Lactate Promotes Tumorigenesis by Modulating MOESIN Lactylation and Enhancing TGF-β Signaling in Regulatory T Cells,” Cell Reports 39, no. 12 (2022): 110986.

[148] J. Lin, G. Liu, L. Chen, H. F. Kwok, and Y. Lin, “Targeting Lactate-Related Cell Cycle Activities For Cancer Therapy,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 1231-1243.

[149] K. M. Maalej, M. Merhi, V. P. Inchakalody, et al., “CAR-Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges And Emerging Therapeutic Advances,” Molecular Cancer 22, no. 1 (2023): 20.

[150] T. Sun, B. Liu, Y. Li, et al., “Oxamate Enhances the Efficacy of CAR-T therapy Against Glioblastoma Via Suppressing Ectonucleotidases and CCR8 Lactylation,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 253.

[151] H. Aghajanian, T. Kimura, J. G. Rurik, et al., “Targeting Cardiac Fibrosis With Engineered T Cells,” Nature 573, no. 7774 (2019): 430-433.

[152] J. G. Rurik, I. Tombácz, A. Yadegari, et al., “CAR T Cells Produced in vivo to Treat Cardiac Injury,” Science 375, no. 6576 (2022): 91-96.

[153] L. Adamo, C. Rocha-Resende, S. D. Prabhu, and D. L. Mann, “Reappraising the Role of Inflammation in Heart Failure,” Nature Reviews Cardiology 17, no. 5 (2020): 269-285.

[154] T. Kao and C. Huang, “Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases,” International Journal of Molecular Sciences 23, no. 2 (2022): 804.

[155] T. T. Seijkens, C. M. van Tiel, P. J. Kusters, et al., “Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis,” Journal of the American College of Cardiology 71, no. 5 (2018): 527-542.

[156] K. Ma, S. Lv, B. Liu, et al., “CTLA4-IgG Ameliorates Homocysteine-Accelerated Atherosclerosis By Inhibiting T-Cell Overactivation in apoE(-/-) Mice,” Cardiovascular Research 97, no. 2 (2013): 349-359.

[157] C. Ma, A. H. Kesarwala, T. Eggert, et al., “NAFLD Causes Selective CD4(+) T Lymphocyte Loss and Promotes Hepatocarcinogenesis,” Nature 531, no. 7593 (2016): 253-257.

[158] C. S. Hong, N. A. Graham, W. Gu, et al., “MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4,” Cell Reports 14, no. 7 (2016): 1590-1601.

[159] R. Plummer, S. Halford, P. Jones, et al., “A First-in-Human First-in-Class (FIC) Trial of the Monocarboxylate Transporter 1 (MCT1) Inhibitor AZD3965 in Patients With Advanced Solid Tumours,” Annals of Oncology 29 (2018).

[160] H. Xian, Y. Liu, A. Rundberg Nilsson, et al., “Metformin Inhibition of Mitochondrial ATP and DNA Synthesis Abrogates NLRP3 Inflammasome Activation and Pulmonary Inflammation,” Immunity 54, no. 7 (2021): 1463-1477.e11.

[161] R. Kristófi and J. Eriksson, “Metformin as an Anti-Inflammatory Agent: A Short Review,” Journal of Endocrinology 251, no. 2 (2021): R11-r22.

[162] A. Petrasca, R. Hambly, N. Kearney, et al., “Metformin Has Anti-Inflammatory Effects and Induces Immunometabolic Reprogramming Via Multiple Mechanisms in Hidradenitis Suppurativa,” British Journal of Dermatology 189, no. 6 (2023): 730-740.

[163] R. Zhou, R. Ding, Q. Yu, et al., “Metformin Attenuates Neutrophil Recruitment Through the H3K18 Lactylation/Reactive Oxygen Species Pathway in Zebrafish,” Antioxidants 13, no. 2 (2024): 176.

[164] X. Mei, et al., “Danshen: A phytochemical and pharmacological overview,” Chinese Journal of Natural Medicines 17, no. 1 (2019): 59-80.

[165] Z. Li, S. Xu, and P. Liu, “Salvia Miltiorrhiza Burge (Danshen): A Golden Herbal Medicine in Cardiovascular Therapeutics,” Acta Pharmacologica Sinica 39, no. 5 (2018): 802-824.

[166] M. Shi, F. Huang, C. Deng, Y. Wang, and G. Kai, “Bioactivities, Biosynthesis and Biotechnological Production of Phenolic Acids in Salvia Miltiorrhiza,” Critical Reviews in Food Science and Nutrition 59, no. 6 (2019): 953-964.

[167] J. Zhu, H. Chen, Y. Le, et al., “Salvianolic Acid A Regulates Pyroptosis of Endothelial Cells Via Directly Targeting PKM2 and Ameliorates Diabetic Atherosclerosis,” Frontiers in Pharmacology 13 (2022): 1009229.

[168] J. Li, Y. Chen, L. Li, et al., “Omics and Transgenic Analyses Reveal that Salvianolic Acid B Exhibits its Anti-Inflammatory Effects Through Inhibiting the Mincle-Syk-Related Pathway in Macrophages,” Journal of Proteome Research 20, no. 7 (2021): 3734-3748.

[169] R. Wang, S. Li, P. Chen, et al., “Salvianolic Acid B Suppresses Hepatic Stellate Cell Activation and Liver Fibrosis by Inhibiting the Nf-κB Signaling Pathway Via miR-6499-3p/LncRNA-ROR,” Phytomedicine 107 (2022): 154435.

[170] X. Li, R. Lao, J. Lei, et al., “Natural Products for Acetaminophen-Induced Acute Liver Injury: A Review,” Molecules (Basel, Switzerland) 28, no. 23 (2023): 7901.

[171] S. Hu, Z. Yang, L. Li, et al., “Salvianolic Acid B Alleviates Liver Injury by Regulating Lactate-Mediated Histone Lactylation in Macrophages,” Molecules (Basel, Switzerland) 29, no. 1 (2024).

[172] M. Zhao, F. Li, Y. Jian, et al., “Salvianolic Acid B Regulates Macrophage Polarization in Ischemic/Reperfused Hearts by Inhibiting mTORC1-Induced Glycolysis,” European Journal of Pharmacology 871 (2020): 172916.

[173] Y. Zhao, Y. Dong, Q. Ge, P. Cui, N. Sun, and S. Lin, “Neuroprotective Effects of Ndeelnk From Sea Cucumber Ovum Against Scopolamine-Induced PC12 Cell Damage Through Enhancing Energy Metabolism and Upregulation of the PKA/BDNF/NGF Signaling Pathway,” Food & Function 12, no. 17 (2021): 7676-7687.

[174] Y. Wu and P. Gong, “Scopolamine regulates the osteogenic differentiation of human periodontal ligament stem cells Through lactylation modification of RUNX2 protein,” Pharmacology Research & Perspectives 12, no. 1 (2024): e1169.

[175] V. Maurya, F. DeMayo, and J. Lydon, “Illuminating the “Black Box” of Progesterone-Dependent Embryo Implantation Using Engineered Mice,” Frontiers in Cell and Developmental Biology 9 (2021): 640907.

[176] W. Zhao, Y. Wang, J. Liu, et al., “Progesterone Activates the Histone Lactylation-Hif1α-glycolysis Feedback Loop to Promote Decidualization,” Endocrinology 165, no. 1 (2023): bqad169.

[177] X. Yin, M. Li, Y. Wang, et al., “Herbal Medicine Formula Huazhuo Tiaozhi Granule Ameliorates Dyslipidaemia Via Regulating Histone Lactylation and miR-155-5p Biogenesis,” Clinical Epigenetics 15, no. 1 (2023): 175.

[178] H. Osama, A. Abdullah, B. Gamal, et al., “Effect of Honey and Royal Jelly Against Cisplatin-Induced Nephrotoxicity in Patients With Cancer,” Journal of the American College of Nutrition 36, no. 5 (2017): 342-346.

[179] Y. Yang, W. Chou, D. A. Widowati, I. Lin, and C. Peng, “10-Hydroxy-2-Decenoic Acid of Royal Jelly Exhibits Bactericide and Anti-Inflammatory Activity in Human Colon Cancer Cells,” BMC Complementary and Alternative Medicine [Electronic Resource] 18, no. 1 (2018): 202.

[180] H. Xu, L. Li, S. Wang, et al., “Royal Jelly Acid Suppresses Hepatocellular Carcinoma Tumorigenicity by Inhibiting H3 Histone Lactylation at H3K9la and H3K14la Sites,” Phytomedicine 118 (2023): 154940.

[181] Y. Yu, X. Huang, C. Liang, and P. Zhang, “Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer,” European Journal of Pharmacology 957 (2023): 176007.

[182] N. Chen, Q. Xie, S. Song, et al., “Dexamethasone Protects Against Asthma Via Regulating Hif-1α-Glycolysis-Lactate Axis and Protein Lactylation,” International Immunopharmacology 131 (2024): 111791.

[183] A. Rauf, M. Imran, T. Abu-Izneid, et al., “Proanthocyanidins: A Comprehensive Review,” Biomedicine & Pharmacotherapy 116 (2019): 108999.

[184] R. de la Iglesia, F. I. Milagro, J. Campión, N. Boqué, and J. A. Martínez, “Healthy Properties of Proanthocyanidins,” Biofactors 36, no. 3 (2010): 159-168.

[185] M. J. Kruger, N. Davies, K. H. Myburgh, and S. Lecour, “Proanthocyanidins, Anthocyanins and Cardiovascular Diseases,” Food Research International 59 (2014): 41-52.

[186] Y. Wu, X. Wang, Y. Zhang, et al., “Proanthocyanidins Ameliorate LPS-Inhibited Osteogenesis of PDLSCs by Restoring Lysine Lactylation,” International Journal of Molecular Sciences 25, no. 5 (2024): 2947.

[187] Y. Lee, B. Cha, S. Choi, et al., “Fargesin Improves Lipid and Glucose Metabolism in 3T3-L1 Adipocytes and High-Fat Diet-Induced Obese Mice,” Biofactors 38, no. 4 (2012): 300-308.

[188] T. Pham, M. Kim, M. Le, et al., “Fargesin Exerts Anti-Inflammatory Effects In THP-1 Monocytes by Suppressing PKC-Dependent AP-1 and NF-ĸB Signaling,” Phytomedicine 24 (2017): 96-103.

[189] Z. Guo, Y. Tang, S. Wang, et al., “Natural Product Fargesin Interferes With H3 Histone Lactylation Via Targeting PKM2 to Inhibit Non-Small Cell Lung Cancer Tumorigenesis,” Biofactors 50, no. 3 (2024): 592-607.

[190] L. Li, Y. Ji, J. Fan, et al., “Demethylzeylasteral (T-96) Inhibits Triple-Negative Breast Cancer Invasion by Blocking the Canonical and Non-Canonical TGF-β Signaling Pathways,” Naunyn-Schmiedebergs Archives of Pharmacology 392, no. 5 (2019): 593-603.

[191] L. Pan, F. Feng, J. Wu, et al., “Demethylzeylasteral Targets Lactate by Inhibiting Histone Lactylation to Suppress the Tumorigenicity of Liver Cancer Stem Cells,” Pharmacological Research 181 (2022): 106270.

[192] X. Li, M. Yao, L. Li, et al., “Aloe-Emodin Alleviates Cerebral Ischemia-Reperfusion Injury by Regulating Microglial Polarization and Pyroptosis Through Inhibition of NLRP3 Inflammasome Activation,” Phytomedicine 129 (2024): 155578.

[193] Y. He, J. Xi, J. Fang, B. Zhang, and W. Cai, “Aloe-Emodin Alleviates Doxorubicin-Induced Cardiotoxicity Via Inhibition of Ferroptosis,” Free Radical Biology and Medicine 206 (2023): 13-21.

[194] Y. Yu, H. Liu, D. Yang, et al., “Aloe-Emodin Attenuates Myocardial Infarction and Apoptosis Via Up-Regulating miR-133 Expression,” Pharmacological Research 146 (2019): 104315.

[195] F. Ouyang, Y. Li, H. Wang, et al., “Aloe Emodin Alleviates Radiation-Induced Heart Disease Via Blocking P4HB Lactylation and Mitigating Kynurenine Metabolic Disruption,” Advanced Science (Weinheim) 11, no. 47 (2024): e2406026.

[196] E. Dai, W. Wang, Y. Li, D. Ye, and Y. Li, “Lactate and Lactylation: Behind the Development of Tumors,” Cancer Letters 591 (2024): 216896.

[197] Z. Wang, D. Hao, S. Zhao, Z. Zhang, Z. Zeng, and X. Wang, “Lactate and Lactylation: Clinical Applications of Routine Carbon Source and Novel Modification in Human Diseases,” Molecular & Cellular Proteomics 22, no. 10 (2023): 100641.

[198] Y. Wang, J. Fan, X. Meng, et al., “Development of Nucleus-Targeted Histone-Tail-Based Photoaffinity Probes to Profile the Epigenetic Interactome in Native Cells,” Nature Communications 16, no. 1 (2025): 415.

[199] F. Li, H. Zhang, Y. Huang, et al., “Single-Cell Transcriptome Analysis Reveals the Association Between Histone Lactylation and Cisplatin Resistance in Bladder Cancer,” Drug Resistance Updates 73 (2024): 101059.

[200] M. Ke, H. Shen, L. Wang, et al., “Identification, Quantification, and Site Localization of Protein Posttranslational Modifications via Mass Spectrometry-Based Proteomics,” Advances in Experimental Medicine and Biology 919 (2016): 345-382.

[201] H. Phukan, A. Sarma, D. A. B. Rex, A. B. Rai, T. S. K. Prasad, and M. G. Madanan, “Unique Posttranslational Modification Sites of Acetylation, Citrullination, Glutarylation, and Phosphorylation Are Found to Be Specific to the Proteins Partitioned in the Triton X-114 Fractions of Leptospira,” American Chemical Society Omega 7, no. 22 (2022): 18569-18576.

[202] K. Sasaki, S. Nishina, A. Yamauchi, et al., “Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice,” Cellular and Molecular Gastroenterology and Hepatology 11, no. 3 (2021): 739-762.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.